Valneva SE (EPA:VLA)
France
· Delayed Price · Currency is EUR 2.402
-0.042 (-1.72%)
Jun 27, 2025, 5:35 PM CET
Valneva SE Revenue
Valneva SE had revenue of 49.23M EUR in the quarter ending March 31, 2025, with 50.31% growth. This brings the company's revenue in the last twelve months to 186.06M, up 21.64% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
186.06M
Revenue Growth
+21.64%
P/S Ratio
2.20
Revenue / Employee
260.95K
Employees
713
Market Cap
408.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 45.17B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| Clariane SE | 5.28B |
Valneva SE News
- 2 days ago - Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - GlobeNewsWire
- 2 days ago - Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance - GlobeNewsWire
- 18 days ago - UK's MHRA suspends Valneva's chikungunya vaccine for elderly - Reuters
- 22 days ago - Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 - Benzinga
- 22 days ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 24 days ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 6 weeks ago - Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States - GlobeNewsWire